Lenalidomide revenue dependency
Significant portion of U.S. growth attributed to lenalidomide; agreement ends January 2026, creating uncertainty beyond.
high · analyst_question
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Russia market volatility
Russia business grew 77% but on a low base; currency and geopolitical risks remain high.
medium · management_commentaryIndia innovation execution risk
Top-5 aspiration relies on signing and commercializing multiple innovative products; timeline and uptake uncertain.
medium · analyst_questionPrice erosion normalization in U.S.
Current lower price erosion may be temporary; management noted model hasn't changed, implying potential reversion.
medium · data_observation